Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients

NCT06577961 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Kidney Cancer
RCC
Renal Cell Carcinoma

Interventions

DRUG: Vorolanib
DRUG: cadonilimab

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences